Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MGC028 |
Synonyms | |
Therapy Description |
MGC028 is an antibody-drug conjugate consisting of an ADAM9 antibody conjugated to a topoisomerase I inhibitor, which potentially inhibits growth of ADAM9-expressing tumors (Cancer Res (2024) 84 (6_Supplement): 1897). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MGC028 | MGC-028|MGC 028 | MGC028 is an antibody-drug conjugate consisting of an ADAM9 antibody conjugated to a topoisomerase I inhibitor, which potentially inhibits growth of ADAM9-expressing tumors (Cancer Res (2024) 84 (6_Supplement): 1897). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06723236 | Phase I | MGC028 | A Study of MGC028 in Participants with Advanced Solid Tumors | Recruiting | USA | 0 |